Status: Not yet recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping
Participants needed: 70
Trial details
Phase: Phase 3Age: 7-16Biological sex: MaleType: InterventionalSponsor: Avidity Biosciences, Inc.Updated: Jul 13, 2026
Eligibility criteria
Ambulatory males with clinical and genetic diagnosis of DMD [+4]
Previous treatment cell or gene therapy. [+4]